Merck and DNAtrix Announce Phase 2 Immuno-Oncology Collaboration in Patients with Aggressive Form of Brain Cancer

Dateline City: KENILWORTH, N.J. & HOUSTON KENILWORTH, N.J. & HOUSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and DNAtrix today announced they have entered into an oncology clinical study collaboration to evaluate the efficacy and safety of DNX-2401, DNAtrix’s oncolytic immunotherapy, in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in a Phase 2, multi-centered study of patients with recurrent glioblastoma, the most aggressive form of brain cancer for which there is no cure. Language: English Contact: MerckMedia Relations:Pamela Eisele, 267-305-3558orAn Phan, 908-255-6325Investor Relations:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879orDNAtrixInvestor/Media Relations:Imran Alibhai, Ph.D.ialibhai@dnatrix.com Ticker Slug: Ticker: MRK Exchange: NYSE read more
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news